tetano
Editor, Senior Moderator
ASAIO J
. 2023 Oct 23.
doi: 10.1097/MAT.0000000000002080. Online ahead of print. Clinical Outcomes of SARS-CoV-2 Infection in Pediatric Patients on Ventricular Assist Device Support: An Action Registry Analysis
Diana M Torpoco Rivera[SUP] 1 [/SUP], Anna Joong[SUP] 2 [/SUP], Nikita D'Souza[SUP] 3 [/SUP], Toni Duganiero[SUP] 3 [/SUP], Angela Lorts[SUP] 3 [/SUP], Joseph A Spinner[SUP] 4 [/SUP]; ACTION Learning Network Investigators
Collaborators, Affiliations
Adult patients on left ventricular assist device (LVAD) support have increased morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. There are no reported clinical data describing outcomes among pediatric patients on ventricular assist device (VAD) support infected with SARS-CoV-2. We conducted a retrospective study using the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry to evaluate patient characteristics and clinical outcomes after SARS-CoV-2 infection. A total of 22 children on VAD support (median age at infection 10.6 years) from 16 centers tested positive for SARS-CoV-2. Cardiomyopathy (59.1%) and congenital heart disease (40.9%) were the most common primary diagnoses. The type of support included LVAD in 19 (86.4%), biventricular assist device (BIVAD) in one (4.5%), and single ventricle VAD in two (9%) patients. At the time of infection, 50% were outpatients, 23% were inpatients on a general cardiology floor, and 27% were in the cardiac intensive care unit (CICU). Most patients (82%) were symptomatic at time of diagnosis, but only 13% required escalation of respiratory support, and 31% received SARS-CoV-2 therapies. Notably, no mortality occurred, and significant morbidity was rare after SARS-CoV-2 infection in pediatric patients on VAD support.
. 2023 Oct 23.
doi: 10.1097/MAT.0000000000002080. Online ahead of print. Clinical Outcomes of SARS-CoV-2 Infection in Pediatric Patients on Ventricular Assist Device Support: An Action Registry Analysis
Diana M Torpoco Rivera[SUP] 1 [/SUP], Anna Joong[SUP] 2 [/SUP], Nikita D'Souza[SUP] 3 [/SUP], Toni Duganiero[SUP] 3 [/SUP], Angela Lorts[SUP] 3 [/SUP], Joseph A Spinner[SUP] 4 [/SUP]; ACTION Learning Network Investigators
Collaborators, Affiliations
- PMID: 37862686
- DOI: 10.1097/MAT.0000000000002080
Adult patients on left ventricular assist device (LVAD) support have increased morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. There are no reported clinical data describing outcomes among pediatric patients on ventricular assist device (VAD) support infected with SARS-CoV-2. We conducted a retrospective study using the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry to evaluate patient characteristics and clinical outcomes after SARS-CoV-2 infection. A total of 22 children on VAD support (median age at infection 10.6 years) from 16 centers tested positive for SARS-CoV-2. Cardiomyopathy (59.1%) and congenital heart disease (40.9%) were the most common primary diagnoses. The type of support included LVAD in 19 (86.4%), biventricular assist device (BIVAD) in one (4.5%), and single ventricle VAD in two (9%) patients. At the time of infection, 50% were outpatients, 23% were inpatients on a general cardiology floor, and 27% were in the cardiac intensive care unit (CICU). Most patients (82%) were symptomatic at time of diagnosis, but only 13% required escalation of respiratory support, and 31% received SARS-CoV-2 therapies. Notably, no mortality occurred, and significant morbidity was rare after SARS-CoV-2 infection in pediatric patients on VAD support.